Clinical and Mutation Spectrum of Autosomal Recessive Non-Syndromic Oculocutaneous Albinism (nsOCA) in Pakistan: A Review

Genes (Basel). 2022 Jun 16;13(6):1072. doi: 10.3390/genes13061072.

Abstract

Oculocutaneous albinism (OCA) is an autosomal recessive syndromic and non-syndromic defect with deficient or a complete lack of the melanin pigment. The characteristics of OCA appears in skin, hair, and eyes with variable degree of pigmentation. Clinical manifestations of OCA include nystagmus, photophobia, reduced visual acuity, hypo-plastic macula, and iris trans-illumination. There are eight OCA types (OCA1-8) documented with non-syndromic characteristics. Molecular studies identified seven genes linked to the OCA phenotype (TYR, OCA2, TYRP1, SLC45A2, SLC24A5, C10orf11, and DCT) and one locus (OCA5) in consanguineous and sporadic albinism. The complications of OCA result in skin cancer and variable syndromes such as Hermansky-Pudlak syndrome (HPS) Chediak-Higashi syndrome (CHS). In the Pakistani population, autosomal recessive non-syndromic OCA is common and is associated with a large number of consanguineous families, and mutations in genes of non-syndromic types are reported. This review highlights the updates on the genetic mutation of OCA genes reported from Pakistani families. Several studies reported the genetic mutations in OCA1, OCA2, OCA3, OCA4, and OCA6 albinism in Pakistani families. A locus, OCA5, was also reported from the Pakistani population, but the gene has not been identified. A new type of OCA8 was identified due to the DCT gene mutation, and it is also reviewed here.

Keywords: albinism; clinical spectrum; consanguinity; genetic mutations; non-syndromic oculocutaneous albinism.

Publication types

  • Review

MeSH terms

  • Albinism* / genetics
  • Albinism, Oculocutaneous* / genetics
  • Carrier Proteins / genetics
  • Humans
  • Mutation
  • Pakistan

Substances

  • Carrier Proteins

Supplementary concepts

  • Oculocutaneous albinism type 2

Grants and funding

This research received no external funding.